Vascular Minimally Invasive Therapy Technology Institute Establishes New Industry-Academia-Clinical Nexus in Hangzhou

Hangzhou, September 9, 2019 /PRNewswire/ -- On September 5, 2019, Hangzhou Wei Qiang Medical Technology Co., Ltd. (hereinafter referred to as "Wei Qiang Medical"), a subsidiary of Deno Medical,The Institute of Minimally Invasive Treatment Technologies for Vascular Diseases (hereinafter referred to as the "Vascular Institute")Officially established in Hangzhou, on the banks of the Qiantang River. The launch ceremony was presided over by Professor Chen Bing, Director of the Department of Vascular Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU). Attendees included Mr. Tang Yin, Director of the Science and Technology Bureau of Binjiang District, Hangzhou; President Wang Jian’an of SAHZU; Mr. Zhao Yiwei, CEO of Deno Medical; and numerous leading experts in vascular surgery, who jointly witnessed the establishment of the Vascular Research Institute.

Medical progress is inseparable from innovation. Over the past decade, China’s field of vascular disease treatment has developed rapidly, with a continuous emergence and iteration of new materials and technologies. Innovative concepts originate from clinical practice, benefit from technological advancements, and evolve through innovation. To better serve patients, it is imperative to deepen basic research on vascular diseases and enhance the standards of diagnosis and treatment. In response, Wei Qiang Medical has established the Vascular Research Institute, aiming to leverage the company’s innovative R&D platform and hospitals’ clinical resources. This initiative seeks to streamline the entire process from clinical needs and technological development to corporate application and industrial translation, promote the integration and synergy of various innovative elements, accelerate the translation of medical-engineering collaborations, and facilitate the application of cutting-edge technologies in addressing minimally invasive treatments for vascular diseases, thereby bringing the benefits of new technologies to more patients.

A Leader in Interventional Devices, a Model for Corporate Development

Tang Yin, Director of the Science and Technology Bureau of Binjiang District, Hangzhou, stated that advanced medical devices constitute a crucial foundation for the development of the biopharmaceutical industry and serve as a primary driver for advancing medical diagnostic and therapeutic technologies. Therefore, vigorously promoting the innovation and development of medical devices holds significant strategic importance. As a leader in the field of peripheral vascular interventional devices, Wei Qiang Medical has jointly established the Vascular Research Institute with leading domestic experts in relevant medical fields. This innovative model, integrating medical practice, research, and enterprise, sets a commendable example for the development of other biopharmaceutical companies. It facilitates the integration of clinical resources from hospitals, leverages the advantages of corporate innovation platforms, promotes technological innovation in medical devices, breaks the monopoly of foreign countries on core technologies, and drives the development of the medical device industry in Binjiang District and even throughout Hangzhou, thereby fostering the integration of “industry, academia, research, medicine, and inspection.” As the Science and Technology Bureau of the High-Tech Zone (Binjiang), the government will fully support the establishment of the Institute for Minimally Invasive Treatment of Vascular Diseases, provide high-quality and efficient government services to projects, experts, and scientific research teams settling in Binjiang, and implement corresponding supporting policies to optimize the entrepreneurial environment.

Wei Qiang Medical: Advancing Patient Welfare in China

Professor Chen Zhong, Director of the Department of Vascular Surgery at Beijing Anzhen Hospital, Capital Medical University, and Chairman of the Executive Committee on Innovation Strategy and Implementation at the Vascular Research Institute, stated: “Innovation is ubiquitous; any new thinking, new model, or new technology constitutes innovation. However, integrating these diverse innovations to distill higher-quality and more meaningful outcomes is precisely the mission our team at the Vascular Research Institute must undertake. Just as strengthening the military is essential to building a strong nation, we as healthcare professionals should advocate for strengthening medicine. ‘Strong medicine’ signifies national health, underpinned by advanced medical technologies, robust medical teams, and comprehensive healthcare security. The foundation of all this lies in medical innovation. The establishment of the Vascular Research Institute today represents a small step forward in medical innovation, and I am confident that the products translated from research by the Institute in the future will enable a giant leap in medical innovation.”

New Bond for Medical-Engineering Integration

Wang Jian’an, President of the Second Affiliated Hospital of Zhejiang University School of Medicine and Director of the Institute of Vascular Diseases, stated that a crucial step for physicians to realize their ideals is to address current challenges. By meeting patient needs and effectively integrating the expertise of clinicians with that of engineers, the establishment of the Institute of Vascular Diseases aims to create a platform that synergizes resources from both medical professionals and industry partners, thereby accelerating the translation of medical-engineering innovations and benefiting more patients.

Chinese-Style Innovation Solutions Based on Clinical Needs

Mr. Zhao Yiwei, Executive Dean of the Vascular Institute and CEO of Deno Medical Group, stated that corporate development is inseparable from high-tech innovation highlights and technological sophistication. Wei Qiang Medical possesses Chinese-style innovative capabilities that meet China-specific needs. Medical research and innovation serve as a crucial pivot for corporate growth and constitute a core competitive advantage; they also align with China’s current national development requirements and the future trends of the healthcare industry. Wei Qiang Medical aims to create a new Chinese-style model of medical-engineering integration, build a new bridge for such collaboration, and achieve the perfect translation of Chinese-style innovation.

Subsequently, Professor Chen Bing, Executive Vice Dean of the Vascular Institute and Director of the Department of Vascular Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), presented the organizational framework and bylaws of the Vascular Institute at the conference. Professor Chen stated that the establishment of the Vascular Institute aims to achieve a win-win outcome by leveraging the institute’s platform to integrate industrial frontier and common technology R&D, corporate innovation resources, and clinical resources from physicians and hospitals, thereby facilitating complementary advantages between innovation and clinical resources.

The Institute of Minimally Invasive Vascular Disease Treatment Technology Officially Launches

Sharing of Excellent Case Studies on Innovative Products

Professor Fu Weiguo of Zhongshan Hospital, Fudan University, and Chairman of the Clinical Research Committee on Innovative Devices and Technologies at the Institute of Vascular Research, shared the Fusmart steerable catheter, co-developed with Wei Qiang Medical.

Professor Guo Wei of the Chinese PLA General Hospital, Chairman of the Committee on Medical Devices and Technological Innovation R&D at the Institute of Vascular Research, shared insights on the modular endovascular stent graft for the aortic arch, co-developed with Wei Qiang Medical.

Finally, Mr. Wang Yongsheng, Executive Vice President of the Vascular Institute and General Manager of Wei Qiang Medical, introduced Wei Qiang’s integrated medical-engineering innovation model to the members of the Vascular Institute. He emphasized that Wei Qiang Medical will fully leverage the resource advantages of the Institute’s platform, always prioritize clinical needs, and remain committed to medical-engineering collaboration, quality, and innovation.

In the future, the Vascular Institute will leverage Hangzhou Wei Qiang Medical Technology Co., Ltd. as its affiliated innovation entity to conduct academic research focused on the development of new devices, validation of novel technologies, and implementation of innovative concepts for peripheral vascular diseases. This initiative aims to benefit patients while advancing the industrial development of vascular disease diagnosis and treatment, as well as innovative minimally invasive techniques, in Zhejiang Province and across China.